A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and
Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects
with Refractory Non-Hodgkin Lymphoma (NHL)
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02519270.
Locations matching your search criteria
United States
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)Status: Active
Name Not Available
This open-label, non-randomized, first-in-human Phase 1 study involves two stages:
In the Dose-Escalation Stage, ascending dose cohorts will be treated in 2 periods until
the maximum tolerated dose is identified. In Period 1, subjects will receive 2 doses of
IGN002 administered weekly. In Period 2, subjects will receive up to 24 additional doses
of IGN002 administered weekly in three 8-week cycles. Subjects that have not progressed
following the treatment period will be followed for another 6 months.
In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the identified
maximum tolerated dose administered weekly in three 8-week cycles. Subjects that have not
progressed following the treatment period will be followed for another 6 months.
Lead OrganizationSpectrum Pharmaceuticals Inc
